For Healthcare Professionals

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors


About the study

The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
  2. Must have advanced/metastatic HCC
  3. Have to be immunotherapy treatment-naive in the advanced/metastatic setting
  4. Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion
  5. Child-Pugh score of 5 or 6
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 for ECOG performance status scale


Key Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
  2. Prior organ allograft or allogeneic bone marrow transplantation
  3. No uncontrolled or significant cardiovascular disease
  4. No active known autoimmune disease
  5. Have received one or two lines of tyrosine kinase inhibitor therapies
  6. Evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy

Other protocol-defined inclusion/exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Jan 31, 2025

Treatment type



Bristol-Myers Squibb identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.